Oceanside, CA, United States of America

David S Lukeman


Average Co-Inventor Count = 4.4

ph-index = 3

Forward Citations = 34(Granted Patents)


Location History:

  • Oceanside, CA (US) (1997 - 2000)
  • Rancho Santa Fe, CA (US) (2000)
  • Milan, IT (1997 - 2002)

Company Filing History:


Years Active: 1997-2002

Loading Chart...
6 patents (USPTO):Explore Patents

Title: Innovations of David S. Lukeman in Thrombosis Treatment

Introduction

David S. Lukeman is a notable inventor based in Oceanside, California. He has made significant contributions to the field of medical science, particularly in the treatment of thrombosis. With a total of six patents to his name, his work focuses on innovative methods and compositions that enhance therapeutic outcomes.

Latest Patents

Among his latest patents, Lukeman has developed methods and compositions for treating thrombosis. One of his inventions involves cyclic peptides that inhibit platelet aggregation without causing prolonged bleeding time. These peptides contain RGD or KGD sequences that are cyclized and feature hydrophobic moieties adjacent to the carboxy terminus of the RGD sequence. Additionally, he has created peptides that possess a high affinity for the receptor IIb/IIIa while maintaining a low affinity for fibronectin and vitronectin receptors. These peptides can be administered in a suitable physiologically acceptable carrier to effectively treat thrombosis.

Career Highlights

Lukeman is associated with the La Jolla Cancer Research Foundation, where he continues to advance his research and innovations. His work has the potential to significantly impact the medical community and improve patient outcomes in thrombosis treatment.

Collaborations

Some of his notable coworkers include Michael D. Pierschbacher and Soan Cheng, who have collaborated with him on various projects.

Conclusion

David S. Lukeman's innovative approaches to treating thrombosis through cyclic peptides demonstrate his commitment to advancing medical science. His contributions are paving the way for new therapeutic options in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…